172 INTERVENČNÍ A AKUTNÍ KARDIOLOGIE / Interv Akut Kardiol. 2023;22(4):166-172 / www.iakardiologie.cz PŘEHLEDOVÉ ČLÁNKY / REVIEW ARTICLES Současný pohled na indikace CTO PCI cutaneous Coronary Intervention of Chronic Total Occlusions: When and How to Treat. Cardiovasc Revasc Med. 2019;20:513-22. 59. Abdullah SM, Hastings JL, Amsavelu S, et al. Percutaneous Coronary Intervention of Coronary Chronic Total Occlusions Improves Peak Oxygen Uptake during Cardiopulmonary Exercise Testing. J Invasive Cardiol. 2017;29:83-91. 60. Mashayekhi K, Neuser H, Kraus A, et al. Successful Percutaneous Coronary Intervention Improves Cardiopulmonary Exercise Capacity in Patients With Chronic Total Occlusions. J Am Coll Cardiol. 2017;69:1095-6. 61. Qintar M, Grantham JA, Sapontis J, et al. Dyspnea Among Patients With Chronic Total Occlusions Undergoing Percutaneous Coronary Intervention: Prevalence and Predictors of Improvement. Circ Cardiovasc Qual Outcomes. 2017; 10:e003665. 62. Rösner A, Avenarius D, Malm S, et al. Severe regional myocardial dysfunction by stress echocardiography does not predict the presence of transmural scarring in chronic coronary artery disease. Eur Heart J Cardiovasc Imaging. 2015;16:1074-81. 63. Bucciarelli‑Ducci C, Auger D, Di Mario C, et al. CMR Guidance for Recanalization of Coronary Chronic Total Occlusion. JACC Cardiovasc Imaging. 2016;9:547-56. 64. Megaly M, Brilakis ES, Abdelsalam M, et al. Impact of Chronic Total Occlusion Revascularization on Left Ventricular Function Assessed by Cardiac Magnetic Resonance. JACC Cardiovasc Imaging. 2021;14:1076-8. 65. Allahwala UK, Brilakis ES, Kiat H, et al. The indications and utility of adjunctive imaging modalities for chronic total occlusion (CTO) intervention. J Nucl Cardiol. 2021;28:2597-608. 66. Schumacher SP, Everaars H, Stuijfzand WJ, et al. Viability and functional recovery after chronic total occlusion percutaneous coronary intervention. Catheter Cardiovasc Interv. 2021;98:E668-76. 67. Schumacher SP, Everaars H, Stuijfzand WJ, et al. Coronary collaterals and myocardial viability in patients with chronic total occlusions. EuroIntervention. 2020;16:e453-61. 68. Serruys PW, Morice MC, Kappetein AP, et al.; SYNTAX Investigators. Percutaneous coronary intervention versus coronary‑artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961-72. 69. Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three‑vessel disease and left main coronary disease: 5-year follow‑up of the randomised, clinical SYNTAX trial. Lancet. 2013;381:629-38. 70. Thuijs DFJM, Kappetein AP, Serruys PW, et al.; SYNTAX Extended Survival Investigators. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with threevessel or left main coronary artery disease: 10-year follow‑up of the multicentre randomised controlled SYNTAX trial. Lancet. 2019;394:1325-34. ODBORNÝ GARANT: prof. MUDr. Michal Vrablík, Ph.D. III. interní klinika 1. LF UK a VFN v Praze POŘADATEL: SOLEN, s. r. o. PARTNER POČET KREDITŮ 2 Registrace ZDARMA TERMÍN září 2023 až srpen 2024 dostupný na online.solen.cz On-line kurz Kardiologie ON LINE KURZ PŘEDNÁŠKY Co je u nových tabulek SCORE opravdu důležité? Modelové situace v ordinaci a jak je řešit – MUDr. Jaromír Ožana, MUDr. Michal Mačák Speciality v léčbě hypertenze – doc. MUDr. Ondřej Petrák, Ph.D. Aktuality a praktické tipy v léčbě dyslipidemie – MUDr. Eva Tůmová, Ph.D. Co (ne)budeme potřebovat od biochemické laboratoře pro stanovení kardiovaskulárního rizika? – prof. MUDr. Michal Vrablík, Ph.D.
RkJQdWJsaXNoZXIy NDA4Mjc=